By Dean Seal
CytomX Therapeutics said it would reduce its organizational headcount by about 40%, primarily affecting staff in general and administrative functions.
The oncology-focused biopharma company said Monday the job cuts are expected to extend its cash runway into the second quarter of 2026.
CytomX expects the restructuring to cost about $5 million to $6 million. The charges will be recorded in the first quarter of this year, when the layoffs are expected to be substantially completed. The costs are related to one-time termination severance payments.
The smaller workforce that remains will prioritize CX-2051, CytomX's tumor-fighting drug candidate.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 06, 2025 17:26 ET (22:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。